PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life
NCT06141434
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
This research study is called 'PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life: The PROMISE Study'. The purpose of this study is to find out more about how exposures during pregnancy, such as having an infection, diet and growth may impact later risk of type 1 diabetes (TID) and islet autoimmunity in the child. We are also interested in finding out more about why having a father or sibling with T1D increases risk of autoimmunity in the child more than having a mother with T1D.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Type 1 Diabetes
- Pregnancy in Diabetic
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 0 days to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of Colorado, Denver
- Last updated on ClinicalTrials.gov
- November 21, 2023
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- University of Colorado · Aurora, CO
Massachusetts · 1
- Joslin Diabetes Center · Boston, MA
New York · 1
- Mt Sinai · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.